XLV ETF Analysis: Health Care Sector Fund | NYSE

Health | NYSE, USA | Market Cap: 43.420m USD | 12M Return: 25.8% | US81369Y2090 | Charts, Fundamentals & Technical Analysis

Pharmaceuticals, Medical Equipment, Biotechnology, Life Sciences
Total Rating 68
Safety 69
Buy Signal 0.04
Health
Category Rotation: -0.6
TER: 0.09%
AUM: 43.4B
Avg Turnover: 1.23B
Risk 3d forecast
Volatility14.3%
VaR 5th Pctl2.46%
VaR vs Median-4.15%
Reward TTM
Sharpe Ratio1.24
Rel. Str. IBD70.3
Rel. Str. Peer Group28.1
Character TTM
Beta0.167
Beta Downside0.175
Hurst Exponent0.428
Drawdowns 3y
Max DD17.11%
CAGR/Max DD0.63
CAGR/Mean DD2.13

Warnings

No concerns identified

Tailwinds

No distinct edge detected

Seasonality 11.6 years of data

Jan -0.4% 8
Feb -0.3% 25
Mar -0.9% 18
Apr +0.2% 2
May -0.3% 18
Jun +0.8% 8
Jul +1.5% 43
Aug -0.2% 0
Sep -1.3% 28
Oct -2.0% 12
Nov +4.6% 43
Dec -0.3% 13

How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.

Description: XLV Health Care Sector Fund

The Health Care Select Sector SPDR Fund (XLV) is an exchange-traded fund that seeks to track the performance of the Health Care Select Sector Index using a full replication strategy, investing at least 95% of its total assets in the underlying index securities. The index spans six healthcare-related industries, including pharmaceuticals, biotechnology, medical equipment, healthcare providers, life sciences tools, and health care technology. The fund is classified as non-diversified, meaning it may concentrate holdings in fewer issuers than a diversified fund.

As a sector-specific ETF, XLV provides investors with targeted exposure to the healthcare industry, which is generally considered a defensive sector due to the relatively inelastic demand for medical products and services regardless of economic conditions. The fund launched in December 1998 and is structured as a large-cap ETF, reflecting the dominance of major pharmaceutical and healthcare equipment companies in the underlying index.

Headlines to Watch Out For
  • GLP-1 obesity drug sales drive pharma revenue growth
  • Medicare drug price negotiations pressure pharma margins
  • Hospital labor costs squeeze healthcare provider margins
What is the price of XLV shares?

As of September 22, 2026, the stock is trading at USD 169.01 with a total of 7,617,550 shares traded. Over the past week, the price has changed by +1.14%, over one month by -2.84%, over three months by +13.06% and over the past year by +25.76%.

Current recommended Stop Loss: 166.20 (which is 1.7% or 1.2 ATR below the current price).

Is XLV a buy, sell or hold?

Health Care Sector Fund has no consensus analysts rating.